Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: The first 10 years
Vascular Endothelial Growth Factor Receptor-2
In our 10-year experience, we have found that SPM development in patients with germline retinoblastoma treated with OAC alone is comparable to previously published rates. In the first 10 years, OAC did not increase the known incidence of SPMs. This cohort will continue to be followed to establish the rate of development with extended follow-up.